Shenzhen YHLO Biotech (SH:688575) Sou Hu Wang·2026-01-20 03:04Group 1 - On January 19, Shenzhen Aihuilong Biotechnology Co., Ltd. (Aihuilong, 688575.SH) established two joint laboratories with Hong Kong University of Science and Technology (Shenzhen) and Shenzhen Technology University, focusing on neurological disease diagnosis and intelligent diagnosis and precision medicine [1][2] - The "Neurodiagnosis Joint Laboratory" will focus on early diagnosis and treatment of neurological diseases, particularly Alzheimer's and Parkinson's diseases, addressing the challenges in the diagnosis of neurological disorders [4][8] - The "Intelligent Diagnosis and Precision Medicine Joint Laboratory" aims to develop AI image recognition systems, microfluidic detection platforms, and new biomarkers, leveraging the strengths of both universities and Aihuilong's market experience [5][7] Group 2 - Aihuilong's collaboration with two universities reflects its commitment to integrating clinical needs with industrial transformation, emphasizing a systematic and long-term partnership approach [8] - The establishment of these laboratories is expected to enhance Aihuilong's product line and technical reserves, contributing to the high-quality development of the biopharmaceutical industry in the Guangdong-Hong Kong-Macao Greater Bay Area [8] - The joint laboratories will facilitate a comprehensive approach from cutting-edge research to clinical application, aiming to create an innovative ecosystem in the health industry [8]